Every 10-Q that Inhibikase Therapeutics Inc (IKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IKT filings page.
Inhibikase Therapeutics is a clinical-stage company focused on IKT-001, a prodrug of imatinib for pulmonary arterial hypertension, now in a single pivotal global Phase 3 IMPROVE-PAH trial with 26 country approvals and 43 sites activated. For the six months ended June 30, 2026, it reported a net loss of $35.97 million, compared with $23.59 million a year earlier, driven mainly by higher research and development expenses of $24.23 million as the Phase 3 program scaled up, and selling, general and administrative expenses of $15.03 million. The company held $159.0 million in cash, cash equivalents and marketable securities at June 30, 2026 and estimates this will fund normal operations for at least 12 months. It also has significant CRO and CMO commitments to support the trial. After quarter-end, it raised additional capital through its at-the-market equity program and received Orphan Drug Designation for IKT-001 in PAH, which may provide tax credits, fee exemptions and potential market exclusivity if the product is approved.
Inhibikase Therapeutics reported a larger quarterly loss as it advances its lead PAH drug IKT-001 into late-stage development. For the three months ended March 31, 2026, the company posted a net loss of $16.4 million, or $0.10 per share, compared with a $13.7 million loss a year earlier. Research and development expenses were $10.8 million, essentially flat year over year after excluding a prior one-time IPR&D charge, while selling, general and administrative costs rose to $7.4 million, driven mainly by higher stock-based compensation.
Other income increased to $1.5 million on interest from cash and marketable securities. Inhibikase ended the quarter with $170.4 million in cash, cash equivalents and marketable securities and an accumulated deficit of about $159.1 million, and believes this cash is sufficient to fund normal operations for at least 12 months. Operationally, the pivotal global IMPROVE-PAH Phase 3 study is enrolling patients, the first patient was enrolled in April 2026, and the company has secured approval to initiate the trial in 16 countries while pursuing approvals in more than 25. Inhibikase also submitted an Orphan Drug Designation application to the FDA for IKT-001 in PAH.
Inhibikase Therapeutics (IKT) reported a larger quarterly loss as it advanced PAH development and integrated an asset acquisition. For Q3 ended September 30, 2025, net loss was $11.93 million, driven by higher research and development expense of $7.65 million and selling, general and administrative expense of $5.61 million. Year-to-date net loss reached $35.52 million.
Liquidity remained solid, with cash, cash equivalents and marketable securities totaling about $77.3 million as of September 30, 2025. Operating cash outflow for the nine months was $20.27 million. The CorHepta acquisition was accounted for as an asset acquisition; the Company expensed acquired IPR&D of $7.36 million and recorded a contingent consideration liability of $2.42 million. IKT entered a global license for risvodetinib, receiving $1 upfront and eligibility for up to $47.5 million in milestones plus double‑digit royalties. An at‑the‑market sales agreement with Jefferies for up to $200 million was established; no sales occurred by quarter end.
Inhibikase Therapeutics (IKT) reported items in its Form 10-Q showing corporate and development activity ahead of a planned Phase 2b study in pulmonary arterial hypertension (PAH). The company expects to initiate a ~150‑patient Phase 2b trial in the second half of 2025 and used non‑human primate safety studies and a bioequivalence trial in healthy volunteers to set dosing.
Financing and equity actions are material: a private placement included issuance of shares and multiple warrant tranches exercisable at $1.37 and $1.49 with exercise and ownership caps, and 19,665,131 pre‑funded warrants were outstanding at June 30, 2025. An at‑the‑market agreement with HCW was terminated effective December 11, 2024; a separate Sales Agreement with Jefferies and a related shelf registration were in place as of June 27, 2025. The company acquired CorHepta, issuing shares including contingent and performance‑based shares and recognized a $7,357,294 R&D write‑off related to IPR&D.